AstaReal files patent for astaxanthin in personalised nutrition

The patent highlights research in which the company’s astaxanthin was able to lower rates of muscle atrophy in response to muscle denervation and nerve injury

AstaReal has filed a patent directly related to personalised nutrition applications of natural astaxanthin in supplements, functional foods, and functional beverages.

Precision nutrition products are tailored to an individual's needs and goals to promote long-term health. AstaReal USA CEO, Arun Nair said: "This is an exciting new path for AstaReal Astaxanthin, addressing the growing contribution of nutrigenomics to the supplement and functional foods market."

Nutrients and bioactive molecules in foods can influence health in many ways; by directly interacting with metabolic pathways, by fuelling growth, and by modulating gene expression. AstaReal's patent enables the company to use astaxanthin in personalised nutrition products aimed at maintaining mobility and healthy muscles. This preventative healthcare approach is relevant for individuals concerned with ageing muscles (i.e. sarcopenia), muscles prone to injury (i.e. athletes), and unloaded muscles (i.e. astronauts). The patent highlights research in which the company’s astaxanthin was able to lower rates of muscle atrophy in response to muscle denervation and nerve injury. It reportedly shifted gene expression profiles to favour the maintenance of healthy muscle mass.

AstaReal USA Scientific Affairs Manager, Dr Karen Hecht said: "The demand for customised nutrition is on the rise, and this AstaReal Astaxanthin patent represents an opportunity to engage in the growing consumer awareness of science-based supplements and their role in tailored nutritional solutions."

Companies